SINUS-24 and SINUS-52

Improvement in sense of smell was investigated in 2 measures: UPSIT score and Daily LoS score.4

UPSIT: Week 24 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS (n=153): 10.52 (95% CI: 8.98, 12.07) (9.71 from a baseline score of 13.53 vs -0.81 from a baseline score of 13.78, respectively).4

Rapid improvement in LoS was observed as early as Day 3.6,a,b (Patient-reported outcome. Results are descriptive. Post hoc analysis. Definitive conclusions cannot be made.)6,a

aLSM difference between DUPIXENT 300 mg Q2W + INCS (n=438) and placebo + INCS (n=286): -0.07 (95% CI: -0.12, -0.02).6,8

bWeek 24 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS (n=153): -0.98 (95% CI: -1.15, -0.81) (-1.21 from a baseline score of 2.77 vs -0.23 from a baseline score of 2.72, respectively) (P<0.0001).4

University of Pennsylvania Smell Identification Test (UPSIT) score (range 0 to 40): higher score indicates improvement.4

Loss of Smell (LoS) score (range 0-3): reduced score indicates improvement.1

INCS, intranasal corticosteroid; LSM, least squares mean; Q2W, once every 2 weeks.

Learn more about how quickly DUPIXENT can improve sense of smell